References
- Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopat Assoc. 2012;112:792–99. https://pubmed.ncbi.nlm.nih.gov/23212430/.
- Swogger MT, Hart E, Erowid F, Erowid E, Trabold N, Yee K, Parkhurst KA, Priddy BM, Walsh Z. Experiences of kratom users: a qualitative analysis. J Psychoact Drugs. 2015;47:360–67.
- Grundmann O. Patterns of kratom use and health impact in the US—Results from an online survey. Drug Alcohol Depend. 2017;176:63–70. doi:10.1016/j.drugalcdep.2017.03.007.
- Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130:127–38. doi:10.1007/s00414-015-1279-y.
- Eastlack S, Cornett E, Kaye A. Kratom-pharmacology, clinical implications, and outlook: a comprehensive review. Pain Ther. 2020;9:55–69. doi:10.1007/s40122-020-00151-x.
- Singh D, Narayanan S, Grundmann O, Dzulkapli E, Vicknasingam B. Effects of kratom (Mitragyna Speciosa Korth.) use in regular users. Subst Use Misuse. 2019;54:2284–89. doi:10.1080/10826084.2019.1645178.
- Müller E, Hillemacher T, Müller CP. Kratom instrumentalization for severe pain self-treatment resulting in addiction - A case report of acute and chronic subjective effects. Heliyon. 2020;6:e04507. doi:10.1016/j.heliyon.2020.e04507.
- Fluyau D, Revadigar N. Biochemical benefits, diagnosis, and clinical risks evaluation of kratom. Front Psychiatry. 2017;8. https://www.ncbi.nlm.nih.gov/pubmed/28484399.
- Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna Speciosa): user demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. 2020;208:107849. doi:10.1016/j.drugalcdep.2020.107849.
- Vicknasingam B, Chooi WT, Rahim AA, Ramachandram D, Singh D, Ramanathan S, Yusof NSM, Zainal H, Murugaiyah V, Gueorguieva R, et al. Kratom and pain tolerance: a randomized, placebo-controlled, double-blind study. Yale J Biol Med. 2020;93:229–38. https://www.ncbi.nlm.nih.gov/pubmed/32607084.
- Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa Korth). Addiction. 2008;103:1048–50. doi:10.1111/j.1360-0443.2008.02209.x.
- Johnson LE, Balyan L, Magdalany A, Saeed F, Salinas R, Wallace S, Veltri CA, Swogger MT, Walsh Z, Grundmann O, et al. The potential for kratom as an antidepressant and antipsychotic. Yale J Biol Med. 2020;93:283–89. https://www.ncbi.nlm.nih.gov/pubmed/32607089.
- Metastasio A, Prevete E, Singh D, Grundmann O, Prozialeck WC, Veltri C, Bersani G, Corazza O. Can kratom (Mitragyna speciosa) alleviate COVID-19 pain? A case study. Front Psychiatry. 2020;11. https://www.ncbi.nlm.nih.gov/pubmed/33329145.
- Bath R, Bucholz T, Buros AF, Singh D, Smith KE, Veltri CA, Grundmann, O. Self-reported health diagnoses and demographic correlates with kratom use: results from an online survey. J Addict Med. 2019. https://www.ncbi.nlm.nih.gov/pubmed/31567595.
- Smith KE, Lawson T. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017;180:340–48. doi:10.1016/j.drugalcdep.2017.08.034.
- Shaik Mossadeq WM, Sulaiman MR, Tengku Mohamad TA, Chiong HS, Zakaria ZA, Jabit ML, Baharuldin MTH, Israf DA. Anti-Inflammatory and antinociceptive effects of Mitragyna speciosa Korth methanolic extract. Med Princ Pr. 2009;18:378–84.
- Prevete E, Kuypers K, Theunissen E, Corazza O, Bersani G, Ramaekers J. A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans. Hum Psychopharmacol. 2021;37. https://pubmed.ncbi.nlm.nih.gov/34309900/.
- Swogger MT, Walsh Z. Kratom use and mental health: a systematic review. Drug Alcohol Depend. 2018;183:134–40. doi:10.1016/j.drugalcdep.2017.10.012.
- Smith KE, Rogers JM, Schriefer D, Grundmann O. Perceived therapeutic benefits with caveats?: analyzing social media data to understand complexities of kratom use. Drug Alcohol Depend. 2021;226:108879. doi:10.1016/j.drugalcdep.2021.108879.
- Hassan Z, Muzaimi M, Navaratnam V, Yusoff NH, Suhaimi FW, Vadivelu R, Vicknasingam BK, Amato D, von Hörsten S, Ismail NIW, et al. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev. 2013;37:138–51.
- Galbis-Reig D. A case report of kratom addiction and withdrawal. Wmj. 2016;115:49–52; quiz 53.
- Suwanlert S. A study of kratom eaters in Thailand. Bull Narc. 1975;27:21–27.
- Sethi R, Hoang N, Ravishankar DA, McCracken M, Manzardo AM. Kratom (Mitragyna Speciosa): friend or foe? Prim Care Companion CNS Disord. 2020;22. https://www.ncbi.nlm.nih.gov/pubmed/31999896.
- Vicknasingam B, Narayanan S, Beng GT, Mansor SM. The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of Peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy. 2010;21:283–88. doi:10.1016/j.drugpo.2009.12.003.
- Corkery JM, Streete P, Claridge H, Goodair C, Papanti D, Orsolini L, Schifano F, Sikka K, Körber S, Hendricks A, et al. Characteristics of deaths associated with kratom use. J Psychopharmacol. 2019;33:1102–23. https://www.ncbi.nlm.nih.gov/pubmed/31429622.
- Snow J, and Mann M. Qualtrics survey software: handbook for research professionals. Seattle, WA, USA: Qualtrics Labs, Inc; 2013.
- Oppe M, Devlin NJ, van Hout B, Krabbe PF, de Charro F. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health. 2014;17:445–53. doi:10.1016/j.jval.2014.04.002.
- Gudex C, Dolan P, Kind P, Williams A. Health state valuations from the general public using the visual analogue scale. Qual Life Res. 1996;5:521–31. doi:10.1007/BF00439226.
- Covvey JR, Vogel SM, Peckham AM, Evoy KE. Prevalence and characteristics of self-reported kratom use in a representative US general population sample. J Addict Dis. 2020;38:506–13. doi:10.1080/10550887.2020.1788914.
- Schimmel J, Amioka E, Rockhill K, Haynes CM, Black JC, Dart RC, Iwanicki JL. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study. Addiction. 2021;116:176–81. https://www.ncbi.nlm.nih.gov/pubmed/32285981.
- Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE. Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend. 2019;202:24–32. doi:10.1016/j.drugalcdep.2019.05.005.
- Winstock A. Global drug survey 2020 executive summary. 2020. https://www.globaldrugsurvey.com/gds-2020-key-findings/
- Back SE, Payne RL, Simpson AN, Brady KT. Gender and prescription opioids: findings from the National Survey on Drug Use and Health. Addict Behav. 2010;35:1001–07. doi:10.1016/j.addbeh.2010.06.018.
- Wilson LL, Harris HM, Eans SO, Brice-Tutt AC, Cirino TJ, Stacy HM, Simons CA, León F, Sharma A, Boyer EW, et al. Lyophilized kratom tea as a therapeutic option for opioid dependence. Drug Alcohol Depend. 2020;216:108310. https://www.ncbi.nlm.nih.gov/pubmed/33017752.
- White CM. Pharmacologic and clinical assessment of Kratom: an update. Am J Health Syst Pharm. 2019;76:1915–25. doi:10.1093/ajhp/zxz221.
- Wilson LL, Chakraborty S, Eans SO, Cirino TJ, Stacy HM, Simons CA, Uprety R, Majumdar S, McLaughlin JP. Kratom alkaloids, natural and semi-synthetic, show less physical dependence and ameliorate opioid withdrawal. Cell Mol Neurobiol. 2021;41:1131–43. https://www.ncbi.nlm.nih.gov/pubmed/33433723.
- Behnood-Rod A, Chellian R, Wilson R, Hiranita T, Sharma A, Leon F, McCurdy CR, McMahon LR, Bruijnzeel AW. Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats. Drug Alcohol Depend. 2020;215:108235. https://www.ncbi.nlm.nih.gov/pubmed/32889450.
- Lucas P, Boyd S, Milloy MJ, Walsh Z. Cannabis significantly reduces the use of prescription opioids and improves quality of life in authorized patients: results of a large prospective study. Pain Med. 2021;22:727–39. doi:10.1093/pm/pnaa396.
- Singh D, Narayanan S, Grundmann O, Boyer EW, Vicknasingam B. The use of benzodiazepines among Kratom (Mitragyna Speciosa Korth.) users. J Psychoactive Drugs. 2020;52:86–92. doi:10.1080/02791072.2019.1632505.
- Matsumoto K, Mizowaki M, Suchitra T, Murakami Y, Takayama H, Sakai S, Aimi N, Watanabe H. Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. Eur J Pharmacol. 1996;317:75–81.
- Singh D, Yeou Chear NJ, Narayanan S, Leon F, Sharma A, McCurdy CR, Avery BA, Balasingam V. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users. J Ethnopharmacol. 2020;249:112462. https://www.ncbi.nlm.nih.gov/pubmed/31816368.
- Prozialeck WC, Avery BA, Boyer EW, Grundmann O, Henningfield JE, Kruegel AC, McMahon LR, McCurdy CR, Swogger MT, Veltri CA, et al. Kratom policy: the challenge of balancing therapeutic potential with public safety. Int J Drug Policy. 2019;70:70–77.
- Vento AE, de Persis S, De Filippis S, Schifano F, Napoletano F, Corkery JM, Kotzalidis GD, et al. Case report: treatment of Kratom use disorder with a classical tricyclic antidepressant. Front Psychiatry. 2021;12. https://www.ncbi.nlm.nih.gov/pubmed/33868054.
- Lei J, Butz A, Valentino N. Management of kratom dependence with buprenorphine/naloxone in a veteran population. Subst Abus. 2021;42:497–502. doi:10.1080/08897077.2021.1878086.
- Stanciu CN, Gnanasegaram SA, Ahmed S, Penders T. Kratom withdrawal: a systematic review with case series. J Psychoact Drugs. 2019;51:12–18. doi:10.1080/02791072.2018.1562133.
- Botejue M, Walia G, Shahin O, Sharma J, Zackria R. Kratom-induced liver injury: a case series and clinical implications. Cureus. 2021;13. https://pubmed.ncbi.nlm.nih.gov/34055525/.
- Eggleston W, Stoppacher R, Suen K, Marraffa JM, Nelson LS. Kratom use and toxicities in the United States. Pharmacotherapy. 2019;39:775–77. doi:10.1002/phar.2280.
- Millson P, Challacombe L, Villeneuve P, Fischer B, Strike C, Myers T, Shore R, Hopkins S, Raftis S, Pearson M, et al. Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations. Can J Public Health. 2004;95:99–103. https://pubmed.ncbi.nlm.nih.gov/15074898/.
- Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, Boyer EW. Suspected adulteration of commercial kratom products with 7-Hydroxymitragynine. J Med Toxicol. 2016;12:341–49. doi:10.1007/s13181-016-0588-y.